Dyax elects new member to board of directors
Dyax Corp. announced today that effective immediately, it has elected to its Board of Directors Susan B. Bayh, J.D., a Washington, D.C. based attorney with significant experience in legal and regulatory affairs. Dyax now has 10 board members with the addition of Bayh, whose experience includes five years working in the legal division of Eli Lilly and Company, where she focused on marketed products, clinical trials and regulatory issues. Bayh currently serves on the boards of biopharmaceutical companies Curis, Inc., Cubist, Inc., Corvas, Inc and Esperion Therapeutics, Inc.
"As we move into advanced stages of clinical development with our lead products DX-88 and DX-890, it is increasingly important that Dyax have first-class capabilities in the areas of legal and regulatory affairs," said Henry E. Blair, Chairman, President and CEO of Dyax. He added, "We already have a superb internal team, now complemented at the board level by Susan's impressive background and broad experience. I am very pleased by the significant addition of Susan to the Dyax board and expect that she will provide valuable counsel as we move our clinical and preclinical programs forward."
Other news from the department people
